Positive News SentimentPositive NewsNASDAQ:INKT MiNK Therapeutics (INKT) Stock Price, News & Analysis $11.86 -0.05 (-0.45%) As of 03:42 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About MiNK Therapeutics Stock (NASDAQ:INKT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get MiNK Therapeutics alerts:Sign Up Key Stats Today's Range$11.64▼$12.1650-Day Range$10.04▼$14.2152-Week Range$6.80▼$76.00Volume9,516 shsAverage Volume166,307 shsMarket Capitalization$59.07 millionP/E RatioN/ADividend YieldN/APrice Target$35.00Consensus RatingHold Company Overview MiNK Therapeutics, Inc. is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors. MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance. The company has established scalable, GMP‐compatible manufacturing processes to produce engineered exosomes at clinically relevant volumes. Research efforts focus on optimizing biodistribution, payload loading efficiency and safety profiles in animal models, with the goal of advancing IND‐enabling studies for first‐in‐human trials. Headquartered in Cambridge, Massachusetts, MiNK collaborates with academic institutions and contract development organizations across North America and Europe to accelerate its research and development programs. The company’s integrated operations encompass discovery, preclinical testing and process development, supported by a team of experts in exosome biology, translational immunology and biomanufacturing. Through these partnerships and internal capabilities, MiNK aims to bring novel, precision immunotherapies to patients with high‐unmet‐need solid tumors.AI Generated. May Contain Errors. Read More MiNK Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks67th Percentile Overall ScoreINKT MarketRank™: MiNK Therapeutics scored higher than 67% of companies evaluated by MarketBeat, and ranked 263rd out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingMiNK Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 1 strong buy rating, 1 buy rating, 2 hold ratings, and 1 sell rating.Upside PotentialMiNK Therapeutics has a consensus price target of $35.00, representing about 192.4% upside from its current price of $11.97.Amount of Analyst CoverageMiNK Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about MiNK Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for MiNK Therapeutics are expected to decrease in the coming year, from ($2.75) to ($2.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MiNK Therapeutics is -4.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MiNK Therapeutics is -4.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about MiNK Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.92% of the float of MiNK Therapeutics has been sold short.Short Interest Ratio / Days to CoverMiNK Therapeutics has a short interest ratio ("days to cover") of 2.73, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MiNK Therapeutics has recently decreased by 0.52%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMiNK Therapeutics does not currently pay a dividend.Dividend GrowthMiNK Therapeutics does not have a long track record of dividend growth. News and Social Media3.7 / 5News SentimentN/A News SentimentMiNK Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for MiNK Therapeutics this week, compared to 3 articles on an average week.MarketBeat Follows2 people have added MiNK Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, MiNK Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $19,140.00 in company stock.Percentage Held by Insiders20.40% of the stock of MiNK Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions2.87% of the stock of MiNK Therapeutics is held by institutions.Read more about MiNK Therapeutics' insider trading history. Receive INKT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MiNK Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INKT Stock News HeadlinesMiNK Therapeutics, Inc. (NASDAQ:INKT) Given Consensus Rating of "Hold" by BrokeragesJune 19, 2026 | americanbankingnews.comInsider Selling: MiNK Therapeutics (NASDAQ:INKT) Director Sells 1,500 Shares of StockJune 6, 2026 | insidertrades.comThe startup growing 23 times faster than NvidiaAn official SEC document contains a name Elon Musk revealed on page 146 - a startup that one analyst believes could be the next monster IPO on Wall Street. This company is growing 23 times faster than Nvidia. The Atlantic called it 'the fastest-growing business in the history of capitalism.' It has nothing to do with robots, self-driving cars, or rockets.June 30 at 1:00 AM | Brownstone Research (Ad)MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders MeetingJune 3, 2026 | globenewswire.comMiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical IllnessMay 28, 2026 | globenewswire.comMiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology CommunicationsMay 20, 2026 | globenewswire.comWe're Not Very Worried About MiNK Therapeutics' (NASDAQ:INKT) Cash Burn RateMay 18, 2026 | finance.yahoo.comMiNK Therapeutics, Inc. (NASDAQ:INKT) Q1 2026 Earnings Call TranscriptMay 16, 2026 | insidermonkey.comSee More Headlines INKT Stock Analysis - Frequently Asked Questions How have INKT shares performed this year? MiNK Therapeutics' stock was trading at $11.15 at the beginning of 2026. Since then, INKT shares have increased by 7.4% and is now trading at $11.97. How were MiNK Therapeutics' earnings last quarter? MiNK Therapeutics, Inc. (NASDAQ:INKT) issued its quarterly earnings data on Friday, May, 15th. The company reported ($0.57) earnings per share for the quarter, topping analysts' consensus estimates of ($0.77) by $0.20. Read the conference call transcript. When did MiNK Therapeutics' stock split? MiNK Therapeutics's stock reverse split on the morning of Tuesday, January 28th 2025.The 1-10 reverse split was announced on Tuesday, January 21st 2025. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did MiNK Therapeutics IPO? MiNK Therapeutics (INKT) raised $43 million in an initial public offering on Thursday, October 14th 2021. The company issued 3,333,334 shares at a price of $12.00-$14.00 per share. How do I buy shares of MiNK Therapeutics? Shares of INKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MiNK Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that MiNK Therapeutics investors own include Agenus (AGEN), HubSpot (HUBS), Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA) and Bank of America (BAC). Company Calendar Last Earnings5/15/2026Today6/30/2026Next Earnings (Estimated)8/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (11m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 INKT's financial health is in the Red zone, according to TradeSmith. INKT has been in this zone for over 11 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:INKT CIK1840229 Webwww.minktherapeutics.com Phone212-994-8250FaxN/AEmployees30Year Founded2017Price Target and Rating Average Price Target for MiNK Therapeutics$35.00 High Price Target$35.00 Low Price Target$35.00 Potential Upside/Downside+195.2%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($2.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$12.49 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-118.57% Debt Debt-to-Equity RatioN/A Current Ratio1.38 Quick Ratio1.38 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($3.03) per share Price / Book-3.91Miscellaneous Outstanding Shares4,982,000Free Float3,966,000Market Cap$59.07 million OptionableNo Data Beta0.47 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free Report This page (NASDAQ:INKT) was last updated on 6/30/2026 by MarketBeat.com Staff. From Our PartnersTrump’s Senior Adviser Sparks a Wealth ShakeupAccording to Bloomberg, Bank of England staff were forced to work overnight as the world's wealthiest investor...Stansberry Research | SponsoredSMX Could Turn Proof Technology into Major Profit!SMX (Security Matters) PLC embeds invisible molecular markers into plastics, metals, fuels, and textiles — con...Smallcaps Daily | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredThe startup growing 23 times faster than NvidiaAn official SEC document contains a name Elon Musk revealed on page 146 - a startup that one analyst believes ...Brownstone Research | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredGold Is About to Do Something It Hasn’t in 90 YearsThe U.S. Treasury still carries America's gold reserves at $42 per ounce — a price set generations ago. Buried...US Gold Bureau | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiNK Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MiNK Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INKT Stock Alerts